PRRT2 and triple-negative breast carcinoma: To see if anti-C2Cat antibodies can detect active PKC in tumor samples and if as the cell lines, triple negative breast tumors have more active cPKC as compared to estrogen receptor positive (ER+) tumors, tissue micro arrays of ER+ and triple negative breast cancer tumor samples were analyzed for their reactivity with anti-C2Cat.